Compared to Estimates, Apellis Pharmaceuticals (APLS) Q4 Earnings: A Look at Key Metrics

Core Insights - Apellis Pharmaceuticals, Inc. reported a revenue of $212.53 million for the quarter ended December 2024, marking a 45.2% increase year-over-year and exceeding the Zacks Consensus Estimate by 8.46% [1] - The company's EPS was -$0.29, an improvement from -$0.73 in the same quarter last year, with a surprise of 25.64% over the consensus estimate of -$0.39 [1] Revenue Breakdown - Product revenue was $191.17 million, surpassing the average estimate of $185.27 million by analysts, reflecting a year-over-year increase of 37.9% [4] - Licensing and other revenue reached $21.36 million, significantly exceeding the nine-analyst average estimate of $12.51 million, representing a year-over-year change of 176.6% [4] - Product revenue from EMPAVELI was $23.36 million, slightly below the average estimate of $24.16 million [4] - Product revenue from SYFOVRE was $167.81 million, exceeding the average estimate of $161.56 million [4] Stock Performance - Over the past month, shares of Apellis Pharmaceuticals have declined by 14.5%, compared to a 2.4% decrease in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]